American Journal of Ophthalmology
Volume 147, Issue 4 , Pages 583-586.e1 , April 2009

Glitazone Use Associated with Diabetic Macular Edema

  • Donald S. Fong

      Affiliations

    • Department of Ophthalmology, Southern California Permanente Medical Group, Baldwin Park, California and Clinical Trials Research, Pasadena, California
    • Corresponding Author InformationInquiries to Donald S. Fong, Clinical Trials Research, SCPMG, 100 S. Los Robles, Pasadena, CA 91101
    • ,
  • Richard Contreras

      Affiliations

    • Department of Research and Evaluation, Southern California Permanente Medical Group, Pasadena, California

,Accepted 13 October 2008.

References 

  1. Stumvoll M, Hfaring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med. 2002;34:217–224
  2. Graham DJ, Green L, Senior JR, Nourjah P. Troglitzaone-induced liver failure: a case study. Am J Med. 2003;114:299–306
  3. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol. 2005;123:1273–1275
  4. Ryan EH, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitzone use. Retina. 2006;26:562–570
  5. Breslow NE, Day NE. Statistical methods in cancer research (Volume II–the design and analysis of cohort studies). IARC Sci Publ. 1987;1–406
  6. Shen LQ, Child A, Weber GM, et al. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol. 2008;126:793–799
  7. Tokuyama T, Ikeda T, Sato K. Effects of haemodialysis on diabetic macular leakage. Br J Ophthalmol. 2000;84:1397–1400
  8. Perkovich BT, Meyers SM. Systemic factors affecting diabetic macular edema. Am J Ophthalmol. 1988;105:211–212
  9. Nesto RW, Bell D, Bonow RO, et al. American Heart Association American Diabetes Association Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941–2948
  10. Avandia. [package insert] http://us.gsk.com/products/assets/us_avandia.pdfAccessed: October 7, 2008
  11. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24:1226–1232
  12. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy. 2002;22:924–929
  13. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289
  14. Bando Y, Ushiogi Y, Okafuji K, et al. Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidae inhibitors. J Int Med Res. 1999;27:53–64
  15. Emoto M, Anno T, Sato Y, et al. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patient and its mRNA in 3T3-L1 adipocytes. Diabetes. 2001;50:1166–1170
  16. Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141:446–455
  17. Do DV, Shah SM, Sung JU, et al. Persistent diabetic macular edema is associated with elevated hemoglobin A1c. Am J Ophthalmol. 2005;139:620–623
  18. Aroca PR, Salvat M, Fernandez J, Mendez I. Risk factors for diffuse and focal macular edema. J Diabetes Complications. 2004;18:211–215
  19. Asensio-Sanchez VM, Gomez-Ramirez V, Morales-Gomez I, Rodriguez-Vaca I. [Clinically significant diabetic macular edema: systemic risk factors]. Arch Soc Esp Oftalmol. 2008;83:173–176
  20. Girach A, Lund-Andersen H. Diabetic macular oedema: a clinical overview. Int J Clin Pract. 2007;61:88–97

PII: S0002-9394(08)00812-X

doi: 10.1016/j.ajo.2008.10.016

American Journal of Ophthalmology
Volume 147, Issue 4 , Pages 583-586.e1 , April 2009

Article Tools